News
ACHV
4.340
-3.56%
-0.160
Weekly Report: what happened at ACHV last week (0219-0223)?
Weekly Report · 2d ago
Weekly Report: what happened at ACHV last week (0212-0216)?
Weekly Report · 02/19 09:39
Weekly Report: what happened at ACHV last week (0205-0209)?
Weekly Report · 02/12 09:36
Weekly Report: what happened at ACHV last week (0129-0202)?
Weekly Report · 02/05 09:38
Weekly Report: what happened at ACHV last week (0122-0126)?
Weekly Report · 01/29 09:36
Achieve Life Sciences Inc: Statement of changes in beneficial ownership of securities
Press release · 01/25 06:07
Weekly Report: what happened at ACHV last week (0115-0119)?
Weekly Report · 01/22 09:37
Weekly Report: what happened at ACHV last week (0108-0112)?
Weekly Report · 01/15 09:36
Weekly Report: what happened at ACHV last week (0101-0105)?
Weekly Report · 01/08 09:37
Weekly Report: what happened at ACHV last week (1225-1229)?
Weekly Report · 01/01 09:35
Weekly Report: what happened at ACHV last week (1218-1222)?
Weekly Report · 12/25/2023 09:38
Weekly Report: what happened at ACHV last week (1211-1215)?
Weekly Report · 12/18/2023 09:40
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC) and Achieve Life Sciences (ACHV)
Analysts maintain Buy ratings on NextCure and Achieve Life Sciences. The two companies are both in the Healthcare sector. The analysts have bullish sentiments on both companies. NextC cure has a price target of $5.67 and Achieve life Sciences has a $21.75.
TipRanks · 12/14/2023 16:50
More
Webull provides a variety of real-time ACHV stock news. You can receive the latest news about Achieve Life Sciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACHV
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company engaged in the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over-the-counter (OTC) products.